Analyst Price Target is $25.00
▲ +10.57% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Oramed Pharmaceuticals in the last 3 months. The average price target is $25.00, with a high forecast of $30.00 and a low forecast of $20.00. The average price target represents a 10.57% upside from the last price of $22.61.
Current Consensus is
The current consensus among 4 polled investment analysts is to buy stock in Oramed Pharmaceuticals. This Buy consensus rating has held steady for over two years.
Oramed Pharmaceuticals, Inc. engages in the provision of oral delivery solutions for drugs delivered via injection. It focuses in the research and development of pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides. The company was founded by Nadav Kidron and Miriam Kidron on April 12, 2002 and is headquartered in New York, NY.